Novartis is trading up 3.10% at $164.19 on November 4, 2026, apparently amid a broader healthcare rally following the midterm election results and a strong overall market. - Healthcare is up 1.37% in the regular session. - Recent coverage focused on the previously disclosed pelacarsen trial failure, not a new announcement explaining the gain. Reuters reported the setback had weighed on shares earlier, making it background to today’s rebound.